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Abstract
Background: Epigenetics is a rapidly evolving field of genetic study applicable to nearly every aspect of
genome-related research. The importance of epigenetics has been recognised in human hepatocellular
carcinoma (HCC). Changes in DNA methylation patterns, including global hypomethylation and promoter
hypermethylation, are thought to be early events in hepatocarcinogenesis.
Objectives: This review aimed to summarise the role of epigenetics in HCC, to describe the mecha-
nisms of epigenetic changes in HCC and to examine the clinical relevance of epigenetics in HCC.
Methods: This review examines the role of CpG-rich regions and DNA methylation, and describes an
epigenetic model of cancer, tumour type-specific methylation, the relationships among methylation,
cirrhosis and hepatocarcinogenesis, and the role of DNA methylation in HCC. The clinical implications of
epigenetics in HCC are discussed.
Results: A multivariate predictor model based on traditional clinical factors and DNA methylation profile
may have important applications in the early detection of neoplastic transformation in populations at high
risk for HCC. CpG methylation may be valuable in HCC prognostics. DNA methylation profiles may enable
clinical prediction in pre-therapy patient biopsies, paraffin-embedded samples or plasma DNA.
Conclusions: Epigenetic changes and profiles may correlate to the biological behaviour of tumours and
clinical outcome of HCC patients. The use of DNA methylation profiles as a surrogate biomarker remains
an active area of clinical cancer research.
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Introduction
Epigenetic mechanisms of carcinogenesis are rapidly becoming
important to the understanding of human malignancies. Tradi-
tionally, genetic instability and mutations are described as
common events in most cancers. A stepwise progression model
involving two discrete genetic pathways has been proposed to
explain the progression to cancer from benign neoplasm to inva-
sive adenocarcinoma.1–3 Oncogene and tumour suppressor gene
mutations that actively control cell proliferation and death (such
as APC, K-ras and p53) and mutations of DNA mismatch repair
genes represent these pathways. In addition to these genetic alter-
ations, cancer initiation and promotion can occur by way of
epigenetic mechanisms.1 It is becoming increasingly clear that
epigenetic events mediate carcinogenesis. Epigenetic alterations
refer to aberrant gene expression profiles that are not caused by
changes in the primary nucleic acid sequence (a classic mutation),
but, rather, involve covalent modification of nucleotide bases in
normal DNA sequences. These changes can occur as part of
normal development, but can also occur as a result of age or
exposure to risk factors, potentially resulting in carcinogenesis in
tissues with normal DNA sequences. Hepatocellular carcinoma
(HCC) typically occurs in the setting of chronic inflammation
secondary to hepatitis B virus (HBV), hepatitis C virus (HCV) or
alcoholism; each aetiology increases the risk for hepatocarcino-
genesis. The purpose of this review is to summarise the role of
epigenetics in cancer with a specific focus on HCC. Furthermore,
we will describe the mechanisms of epigenetic changes in HCC
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and the clinical relevance of epigenetics in the prognosis and
detection of HCC.
CpG islands and DNA methylation
Methylation of cytosine is the only modification of DNA in
mammals known to naturally occur and cytosine-phosphate-
guanine (CpG) site methylation is the best characterised epigenetic
alteration.4 CpG dinucleotides are not uniformly distributed
throughout the human genome. In the vast majority of the
genomic sequence, CpGs occur at a frequency of approximately
one per 80 dinucleotides. However, CpG-rich regions (200 base-
pairs to several kilobases in length), referred to as CpG islands,
comprise 1–2% of the genome.5 Despite the under-representation
of CpG dinucleotides in the mammalian genome, it is estimated
that about 45 000 CpG islands exist in proximity to various gene
promoter regions. Nearly 50–60% of all genes have an associated
CpG island in the 5′ area, often encompassing the promoter and
transcription start site.6 CpG islands are normally unmethylated
and the molecular mechanisms maintaining normal methylation
status remain under investigation. Inappropriate methylation of
the cytosine bases in CpG islands interferes with promoter function
of the gene. Excessive hypermethylation can lead to the transcrip-
tional silencing of genes critical to the normal anti-neoplastic
process (i.e. blocking tumour suppressor gene function).7
However, hypermethylation of promoter regions that bind tran-
scriptional repressors can lead to increased transcription by inter-
fering with the action of the repressor.8
Methylation of the 5′ position of cytosine leads to the formation
of 5-methylcytosine (5-MC), a reaction catalysed by DNA methyl-
transferases (DNMTs). DNA methylation patterns are established
early during development and are relatively constant afterwards, as
methylated CpG dinucleotides are passed on to daughter cells.4,9
Specific proteins that bind to CpG islands and protect them from de
novo methylation are postulated to be involved in this occurrence,
including proteins containing a zinc (Zn) finger binding domain
specific to non-methylated CpG regions and various histone dem-
ethylases that can actively demethylate CpG islands (Fig. 1). In
addition, there is probably a critically important embryological
function associated with DNA methylation because DNA methyl-
transferase knockout mice are non-viable.10 Furthermore,
increased methylation of specific genes, such asMYOD1 andN33 in
normal colon tissue of ageing individuals, may occur as a compo-
nent of the normal ageing process.11
Epigenetic model of cancer
This model suggests that the predominant role of epigenetic
changes involves tissue-specific alterations, ultimately leading to
carcinogenesis. Epigenetics can play a role as one of the ‘first hits’ in
the development of cancer referred to in the Knudson ‘two-hit’
model.12 Along this line, Feinberg et al. described the epigenetic
progenitor model of cancer as involving three steps in tumour
development beginning with early epigenetic changes.13 These epi-
genetic changes, when occurring in tissue progenitor or stem cells,
result in either increased expansion of this population or alter-
ations increasing susceptibility to neoplastic changes. The second
step involves genetic mutation within this cell population, resulting
in cancer. Once cancer is developed, there is enhanced genetic and
epigenetic plasticity (an increased ability for further phenotype
changes brought on by DNA and chromatin instability). This
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Figure 1 Schematic demonstrating how epigenetic DNA methylation blocks gene promoter function. (A) Areas rich in cytosine-phosphate-
guanine (CpG) are preferentially located at or near promoters of genes. Normal gene expression is promoted by zinc finger proteins (Zn
fingers) and histone demethylases inhibiting methylation of the CpG sites. (B) Loss of Zn finger and histone demethylase proteins and/or
increased 5-DNA methyltransferase activity results in increased CpG methylation and subsequent gene silencing. Silencing of tumour
suppressor genes in this manner can lead to carcinogenesis
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contributes to tumour heterogeneity and the development of
metastatic and drug-resistant phenotypes (Fig. 2).13
Additional models describing the role of epigenetics in cancer
have been described. Kopp-Schneider et al. used mathematical
modelling to suggest that the epigenetic changes resulting in
cancer follow a model of tumorigenesis called a ‘colour shift’, in
which an entire colony of cells shifts to cancer, as opposed to the
clonal model, in which cancer begins from a single cell trans-
formation.14 Their analysis showed evidence for this model in
HCC development. A shift in an entire colony of cells could be
explained by epigenetic alterations that prime a group of cells for
the ultimate inciting insult that results in cancer development.
Whether HCC is generated from a single cellular transformation
or multiple cellular changes, there is strong evidence for the cre-
ation of ‘epigenetic fields’ that predispose to cancer development.
Epigenetic silencing of a DNA repair gene (MGMT) has been
defined as one such field defect, in which the resulting altered
methylation of genes creates a pre-neoplastic state in liver, colon,
oesophageal, lung, breast and renal cancers.15,16
There has been increasing interest in stem cells in the develop-
ment and progression of cancer. A stem cell niche has been
described in the liver, composed primarily of clonal cells in the
canal of Hering near the periportal space. When activated, these
cells proliferate in a cord-like fashion towards the hepatic veins to
regenerate the liver.17–19 These cells are particularly important
in severe and chronic injury in which hepatocyte replication is
insufficient and progenitor cells are primarily responsible for
regenerating the parenchyma. In diseased liver, these progenitor
populations are surrounded by inflammatory cells, such as myofi-
broblasts and macrophages.20 Knudson acknowledged that the
proliferation of stem cells is a critical phenomenon in the develop-
ment of cancer because proliferating stem cells can obtain neoplas-
tic mutations at a higher rate. This theory is supported in tumour
development.12 The dependence on progenitor cell activation in
chronic liver injury makes it highly likely that progenitor cells are
involved in the development of HCC and are primed for neoplastic
development through epigenetic modification.
Characterising the epigenetic modulation of the cancer stem
cell (CSC) population in HCC requires further investigation, as
the markers are still to be clearly defined. Side populations isolated
using CD133 have been described; however, the resulting refer-
ence standard tumorgenicity studies in mice have not consistently
confirmed an HCC stem cell population.19 CD90 expression has
been associated with an increasingly tumorigenic population, par-
ticularly when associated with CD44 co-expression in HCC.
Yamashita et al. used the classic CSC marker, EpCAM, to isolate a
CSC-enriched HCC population.21 These cells showed increased
sphere formation and were more tumorigenic in vivo compared
with EpCAM- cells.22 Lingala et al. showed that staining for
CD133+/ALDH+ cells alone, or in combination with CD44 and
CD90, was able to identify putative CSCs in HCC specimens;
however, non-malignant specimens also expressed these mark-
ers.23 Novel markers continue to be identified, including Transge-
lin, which is over-expressed 25-fold in tumorigenic HCC cells
from the Huh7 line.24 Marquardt et al. directly implicated epige-
netic changes with HCC CSCs by inhibiting methylation in
human cell lines using a DNMT1 inhibition. The reduced methy-
lation resulted in increased tumorgenicity of the cells in the
isolated CSC side population.22 Further study is needed to defi-
nitively identify the CSC population in HCC, which will aid
in the characterisation of the genetic and epigenetic changes
involved in these progenitor cells and possibly open the door to
better clinical and therapeutic prognostic indicators and targets.
Tumour type-specific methylation
Unique epigenetic changes have been identified in different genes
in different tumour types, revealing site-specific methylation
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Figure 2 Progenitor cell model of DNA methylation and hepatocarcinogenesis. The development of cancer is initiated by a genetic or
epigenetic ‘first hit’, which increases progenitor cell proliferation. A genetic and epigenetic ‘second hit’ results in neoplastic transformation
of a progenitor cell or a ‘colour shift’ of a population of cells. These transformed cancer cells proliferate to form a tumour and, through
increased genetic and epigenetic instability, develop additional phenotypes resulting in heterogeneous tumour cell populations
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profiles. Esteller et al. used a candidate gene approach to look for
aberrant promoter methylation profiles in 12 genes in 600 primary
tumour samples from 15 major tumour sites.25 They found at least
one or more genes to be hypermethylated in each tumour type and
site-specific profiles began to emerge. Gastrointestinal tumours
had increased methylation of p16INK4a, p14ARF, MGMT, APC and
hMLH1, whereas head, neck and lung tumours were hypermethy-
lated at DAPK, MGMT and p16INK4a, but not at hMLH1 or p14ARF.
Breast and ovary cancer methylated genes includedBRCA1,GSTP1
and p16INK4a.25 Additionally, there appear to be tissue-specific
methylation profiles that develop over time as individuals age.
Autopsy studies by Waki et al. showed that there was specific
methylation in organs, similar to the trends in the corresponding
site-specific tumours.26 In patients over 42 years of age, methylated
promoters were found with increased frequency in: APC in the
stomach, duodenum, liver, pancreas and lung; E-cadherin and
DAP-kinase in the stomach and intestines;RASSF1A in the rectum,
liver, pancreas and kidney, and p16 and RUNX3 in the stomach.26
Specific epigenetic alteration patterns in the key oncogenes and
tumour suppressor genes in HCC have been described. Many of
these sites are common cancer initiators, involving changes to
TP53, B-catenin, ErbB receptors, MET, hepatocyte growth factor
(HGF), p16INK4a, E-cadherin and cyclooxygenase 2 (COX-2).27
Hypermethylation of p16INK4a can occur in early HCC. Maeta et al.
observed that when HCC cells were treated with demethylating
agents, there was increased expression of p16INK4a and subsequent
cell growth inhibition, suggesting that modulation of the epige-
netic control of these genes may be an important target in HCC
therapeutics.28 Lee et al. examined 60 paired HCC and non-HCC
human liver samples to screen for hypermethylation.29 The most
frequent hypermethylated genes in HCC were found to be APC
(81.7%), GTP1 (76.7%), RASSF1a (66.7%), p16 (48.3%), COX-2
(35.0%) and E-cadherin (33.3%). COX-2, p16, RassF1A and
TIMP-3 were specifically associated with HCC and not methylated
in cirrhosis or chronic hepatitis.29
Methylation, cirrhosis
and hepatocarcinogenesis
Epigenetic changes in normal tissue may be precursor events that
increase the likelihood of developing cancer. As cirrhosis is often a
precursor to HCC, it is possible that cirrhosis, caused by chronic
hepatocyte injury and inflammation, leads to global DNA hyper-
methylation. The data to support this theory appear to be con-
flicting. Kondo et al. found no difference in DNA methylation
between normal and cirrhosis liver.16 However, other investigators
demonstrated increased methylation and loss of tumour suppres-
sor gene function in patient samples of cirrhosis and/or chronic
hepatitis.30 Increased methylation of the p16 promoter appears to
be involved in the pathogenesis of HCC, and hypermethylation of
p16 gene is thought to be an inactivating mechanism.31 This obser-
vation clearly supports a multistep hepatocarcinogenesis from
cirrhotic nodules (CNs) through dysplastic nodules (DNs). They
thus examined the methylation status of p16 in HCCs surrounded
by DNs and CNs to define the significance of p16 hypermethyla-
tion in the early stage of hepatocarcinogenesis. In addition, the
p16 methylation status of HCC cell lines (with or without HBV
infection) was tested and HBV-infected cell lines were found to
be exclusively methylation-positive. Other investigators demon-
strated a stepwise progression (from normal liver to HCC) in the
methylation of APC, GSTP1, RASSF1A, p16, COX-2 and
E-cadherin.29 Thus, there appears to be a growing body of evidence
that would suggest that cirrhosis appears to induce or is associated
with DNA methylation and that these epigenetic changes are early
events in hepatocarcinogenesis (Fig. 3).
DNA methylation in HCC
The contribution of DNA methylation to the development of
HCC is not well understood. The study of methylation in HCC is
also challenging as there are several well-known risk factors for
HCC, such as alcohol-induced cirrhosis and chronic viral hepati-
tis B or C infection. Whereas colorectal cancer (CRC) typically
develops in otherwise ‘normal’ colonic tissue, HCC routinely
arises in a distinctly abnormal and often cirrhotic liver. Thus, the
cirrhotic liver may be thought of as an epigenetic field suited for
hepatocarcinogenesis. It is possible that differential promoter
methylation occurs in: (i) normal liver; (ii) cirrhotic liver, and (iii)
HCC. Because cirrhosis is in the causal pathway (from normal
liver to HCC), it is by definition not a confounding factor, but
induces interactions resulting in carcinogenesis (Fig. 4). Thus,
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Figure 3 The role of cirrhosis as it relates to DNA methylation. Cirrhosis plays an important role in the development of hepatocellular
carcinoma (HCC). This can result from epigenetic changes and can also cause epigenetic and genetic changes that ultimately lead to HCC.
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high-throughput analysis of global methylation must take into
account the appropriate control group because the comparison of
methylation in HCC with that in completely normal liver tissue
may not be valid.
Currently, the role of DNA methylation in hepatocarcinogen-
esis is under more scientific scrutiny. Hepatocellular carcinoma
promoter methylation and the subsequent loss of protein expres-
sion have been demonstrated to involve the tumour suppressor
p16, E-cadherin, p15, SOCS1 and RIZ1.32–37 However, not all of
these studies demonstrated the combination of increased DNA
methylation and decreased protein expression.36,37 Recently,
several studies have examined global CpG promoter methylation
in HCC patient samples. Archer et al. recently published HCC
methylation data for normal liver tissue, HCV-infected liver tissue
and HCC.38 In this report, a paired analysis was performed
between HCV–HCC and adjacent HCV–cirrhotic liver tissue. A
total of 56 CpG sites (corresponding to 49 genes) were differen-
tially methylated, with the APC gene located on chromosome 5
demonstrating significant promoter hypermethylation. Ingenuity
Pathways Analysis software was also used to examine genomic
pathways that appeared to be affected by promoter methylation.
Two signalling pathways identified included transforming growth
factor-b (TGF-b) and hepatic fibrosis/hepatic stellate cell activa-
tion.38 It is well known that HCV infection leads to chronic
inflammation and possibly to hepatic stellate cell activation/
fibrosis. Therefore, continued hepatocyte damage as a result of
HCV infection appears to lead to promoter methylation and sub-
sequent HCC.
Several reports have described APC gene promoter hyperm-
ethylation in HCC. However, conflicting reports have detailed
APC promoter methylation in adjacent non-cancerous liver tissue.
Archer et al. found no evidence of hypermethylation, whereas
Csepregi et al. found hypermethylation of APC in 82% of non-
cancerous specimens.38,39 However, Csepregi et al. found that APC
protein expression was significantly reduced in HCC samples
compared with samples of the adjacent non-tumour tissue.39
These results imply that promoter methylation of the APC gene is
a key component of carcinogenesis in HCC because the product of
the gene encodes a tumour suppressor that has been extensively
studied in CRC. Other candidate genes have also been studied. He
et al. showed hypermethylation of the tumour suppressor small
heterodimer partner (SHP) in 10 matched pairs of liver and HCC
tissue, which corresponded to decreased SHP mRNA in HCC
tissues.40 Thus, they concluded that SHP hypermethylation may be
a common event in the development of HCC.40 Although these
studies provide important information as to potential mecha-
nisms of epigenetic events in HCC formation, they have not been
used to correlate methylation with clinical variables such as stage,
response to treatment or outcome.
Clinical implications of the epigenetics of HCC
The accumulating evidence for epigenetic defects in cancer may be
potentially useful in cancer diagnosis and treatment. First, as
described above, aberrant promoter methylation occurs very early
during carcinogenesis and can be detected in the normal epithe-
lium of some patients (i.e. in patients with chronic HBV or HCV).
High degrees of methylation are thought to be associated with an
increased risk for neoplastic transformation. Indeed, aberrant
CpG island methylation in non-cancerous tissues has been
detected in the colons of older people, patients with ulcerative
colitis, in the livers of patients with chronic viral hepatitis, in the
lungs of heavy smokers and in Barrett’s oesophagus, all conditions
of increased risk for cancer development.41–45 DNA methylation
status will also be valuable as a prognostic indicator. Cheng et al.
showed that the high CpG island methylator phenotype CIMP
(defined as having four or five of 10 commonly methylated genes
in HCC) correlated with worse prognosis, increased tumour–
node–metastasis (TNM) stage, increased metastasis and increased
gamma-glutamyl transferase (GGT) levels in HCC patients com-
pared with those with less hypermethylated candidate genes.46
Further understanding of the commonly methylated genes in
HCC may be very valuable in guiding treatment options based on
an improved understanding of patient prognosis.
Ongoing studies will address whether DNA methylation mea-
surement (and, importantly, which gene and which technique)
may be useful in predicting an individual patient’s risk for
tumour development. Second, it is apparent that, in a growing
list of specimens, such as sputum, serum, urine and breast ductal
fluid, promoter hypermethylation can be detected in early-stage
cancers. The limitations of current detection methods using
bisulphate treatment followed by methylation-specific poly-
merase chain reaction (MSP) can lead to degradation of poten-
tially already scarce methylated DNA in serum and body fluids.
Sakamoto et al. proposed one novel detection method utilising
immunoprecipitation with anti-histone antibodies to improve
isolation of methylated DNA.47 Using this technique, they were
able to improve detection of serum p16 methylation in p16
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Figure 4 Proposed pathway relating epidemiological exposures to
the development of hepatocellular carcinoma (HCC). Acquired
disease results in chronic hepatic insults, which accumulate and
result in the development of HCC. HCV, hepatitis C virus; HBV,
hepatitis B virus
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methylation-positive colon cancer patients, with overall detec-
tion rates of 81% vs. 59% and detection rates of 91% vs. 45% in
stage II patients.47 Techniques like this, which improve the sen-
sitivity of detection, may be of significant value to patients,
particularly those at the vital stages of disease in which early
detection may have drastic results on outcome. Marker selection
will also be key to providing appropriately sensitive assays and
screens using epigenetic markers. Glockner et al. described
methylated tissue factor pathway inhibitor 2 (TFPI2), which was
detectable in stool from stage I–III CRC patients with a sensi-
tivity of 76–89% and a specificity of 79–93%.48 Markers such as
these can potentially augment current detection methods and
improve the early diagnosis of various tumours.
The effects of chemotherapeutic agents that induce hypom-
ethylation may be beneficial in the short-term, but they may allow
progression and recurrence from cancer cells that survive or are
even enhanced by DNA hypomethylation (an independent factor
in cancer progression and formation).49 As described in the epi-
genetic progenitor model of cancer proposed by Feinberg et al,13
although early epigenetic changes can prime cells for neoplastic
transformation, they also continue to contribute to the heteroge-
neity of tumours and thus may represent a mechanism of
chemoresistance. Lu et al. recently described the role of Tip30 as a
putative tumour suppressor gene, which is frequently downregu-
lated in several human tumour cells and was identified as a novel
metastasis suppressor gene in small cell lung cancer.50 Its expres-
sion has been detected in many normal human tissues; however, in
HCC, melanoma, breast cancer and CRC, its expression was found
to be decreased.50–55 Methylation of Tip30 was positively associated
with tumour recurrence and poor prognosis in patients with
HCC, which suggests that Tip30 may be a novel marker for pre-
dicting prognosis in patients with HCC and opens the door to the
potential development of Tip30-targeted therapy.50
The availability of methylation array chips has allowed global
CpG analysis. Recently, Hernandez-Vargas et al. published a rather
unique paper in which the global methylation profile (methylome)
was studied in 30 HCC tumours.56 This study employed the Illu-
mina GoldenGate methylation assay and probed 1505 CpG sites,
which correspond to 807 cancer-related genes.56 After filtering for a
P-value of < 0.001 and correcting for a false discovery rate of < 0.1,
124 CpG sites among 94 genes were differentially methylated when
compared with surrounding non-cancerous liver tissue. In addi-
tion, there appeared to be differentially methylated promoters
when comparing: (i) early-stage with later-stage tumours; (ii)
well-differentiated with poorly differentiated tumours, and (iii)
cirrhotic with non-cirrhotic liver tissue. Interestingly, DNMT1
was hypermethylated in poorly differentiated tumours. Another
unique finding of this study was the ‘survival risk prediction’
function data using BRB-ArrayTools.56 This analysis yielded 10
CpG sites (FAT, MYLK, FLT1, CDKN1C, TFPI2, PDE1B, MME,
IGF1R, COL1A2 and TP73) with the highest ability to predict
survival (high-risk vs. low-risk). However, these very interesting
findings should be viewed and interpreted with caution for several
reasons. Firstly, the overall sample size (n = 30) was relatively small.
Secondly, the aetiology of HCC was HBV (n = 9), HCV (n = 5),
alcohol-related (n= 8) and unknown (n= 8). Currently, in the USA,
HCV, not HBV, is the primary epidemiological factor associated
with HCC. Thirdly, other specific treatment and co-morbidity data
are lacking. Lastly, overall survival would appear to be much longer
than expected based upon recent data from the USA, which may
limit the external validity of the study data.57 The important expan-
sion of studies like this will need to identify effective epigenetic
markers for HCC in a larger cohort. Furthermore, the clinical
application of this panel may be particularly limited in the setting
of acute or chronic inflammation and cirrhosis, as these states have
all been shown to share epigenetic markers with HCC. Focusing on
COX-2, p16, RassF1A, TIMP-3 and RUNX3 may increase the abil-
ity to make this distinction because, as discussed above, these are
not epigenetically modified in non-malignant tissue.58,59 Further
studies should validate these and other markers to clearly distin-
guish HCC from non-malignant hepatic pathology commonly
present in patients. This specificity would increase the potential to
develop effective serum or blood tests to identify advancement to
early HCC and offer the best chance of cure.
Future directions
Although some may argue that early detection of HCC has
improved, there are no widely accepted and utilised screening
protocols in the USA. The US Preventative Services Task Force
(USPSTF) has no recommendation for HCC screening and the
American Association for the Study of Liver Disease (AASLD)
guidelines60 may be too general. Most studies from the western
hemisphere would indicate that the diagnosis is established only
in advanced stages. Thus, there is a pressing need for additional
modes of providing earlier diagnosis, establishing a response to
therapy and predicting recurrence. This is problematic in HCC
because numerous staging systems have been developed for prog-
nostic information.61 It is possible that biomarkers and/or methy-
lation profiles may be used as prognostic factors as an adjunct
to staging systems for future clinical trials. The strength of DNA
hypermethylation profiles is underscored by their validation and
the stability of DNA relative to RNA, making methylation pro-
filing a tool better suited to clinical settings.62 A multivariate
predictor model based upon traditional clinical factors and DNA
methylation profile may have important applications in the early
detection of neoplastic transformation in populations at high risk
for HCC. CpG methylation is already being linked to prognosis in
oesophageal cancer, outcome in CRC following surgery and fluo-
rouracil (5-FU), neuroblastoma, ovarian cancer, acute lympho-
blastic leukaemia and gastric cancer,63 and thus may be valuable in
HCC prognostics. In addition, the availability of DNA methyla-
tion profiles to predict survival outcome and response to treat-
ment may enable clinical prediction in pre-therapy patient
biopsies, paraffin-embedded samples or plasma DNA. The ideal
methylation signatures for HCC remain to be defined and there is
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great heterogeneity amongst the different systems that use epige-
netic targets as prognostic or therapeutic markers. Therefore, cur-
rently the role of epigenetics in HCC is very limited for the
hepatobiliary surgeon and these multivariate signatures require
prospective validation with larger cohorts before their clinical
application can be considered.
Conflicts of interest
None declared.
References
1. Soreide K, Nedrebo BS, Knapp JC, Glomsaker TB, Soreide JA, Korner H.
(2009) Evolving molecular classification by genomic and proteomic biom-
arkers in colorectal cancer: potential implications for the surgical oncolo-
gist. Surg Oncol 18:31–50.
2. Fearon ER, Vogelstein B. (1990) A genetic model for colorectal tumori-
genesis. Cell 61:759–767.
3. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J et al.
(2002) Mutations in APC, Kirsten-ras, and p53 – alternative genetic path-
ways to colorectal cancer. Proc Natl Acad Sci U S A 99:9433–9438.
4. Zingg JM, Jones PA. (1997) Genetic and epigenetic aspects of DNA
methylation on genome expression, evolution, mutation and carcinogen-
esis. Carcinogenesis 18:869–882.
5. Gardiner-Garden M, Frommer M. (1987) CpG islands in vertebrate
genomes. J Mol Biol 196:261–282.
6. Smiraglia DJ, Rush LJ, Fruhwald MC, Dai Z, Held WA, Costello JF et al.
(2001) Excessive CpG island hypermethylation in cancer cell lines versus
primary human malignancies. Hum Mol Genet 10:1413–1419.
7. Costello JF, Plass C. (2001) Methylation matters. J Med Genet 38:285–
303.
8. Nabilsi NH, Broaddus RR, Loose DS. (2009) DNA methylation inhibits
p53-mediated survivin repression. Oncogene 28:2046–2050.
9. Sun L, Hui AM, Kanai Y, Sakamoto M, Hirohashi S. (1997) Increased DNA
methyltransferase expression is associated with an early stage of human
hepatocarcinogenesis. Jpn J Cancer Res 88:1165–1170.
10. Li E, Bestor TH, Jaenisch R. (1992) Targeted mutation of the DNA meth-
yltransferase gene results in embryonic lethality. Cell 69:915–926.
11. Horii J, Hiraoka S, Kato J, Harada K, Kuwaki K, Fujita H et al. (2008)
Age-related methylation in normal colon mucosa differs between the
proximal and distal colon in patients who underwent colonoscopy.
Clin Biochem 41:1440–1448.
12. Knudson AG. (1996) Hereditary cancer: two hits revisited. J Cancer Res
Clin Oncol 122:135–140.
13. Feinberg AP, Ohlsson R, Henikoff S. (2006) The epigenetic progenitor
origin of human cancer. Nat Rev Genet 7:21–33.
14. Kopp-Schneider A, Portier C, Bannasch P. (1998) A model for hepato-
carcinogenesis treating phenotypical changes in focal hepatocellular
lesions as epigenetic events. Math Biosci 148:181–204.
15. Ushijima T. (2007) Epigenetic field for cancerization. J Biochem Mol Biol
40:142–150.
16. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S.
(2000) Genetic instability and aberrant DNA methylation in chronic hepa-
titis and cirrhosis – a comprehensive study of loss of heterozygosity and
microsatellite instability at 39 loci and DNA hypermethylation on eight
CpG islands in microdissected specimens from patients with hepatocel-
lular carcinoma. Hepatology 32:970–979.
17. Fellous TG, Islam S, Tadrous PJ, Elia G, Kocher HM, Bhattacharya S et al.
(2009) Locating the stem cell niche and tracing hepatocyte lineages in
human liver. Hepatology 49:1655–1663.
18. Gaudio E, Carpino G, Cardinale V, Franchitto A, Onori P, Alvaro D. (2009)
New insights into liver stem cells. Dig Liver Dis 41:455–462.
19. Alison MR, Islam S, Lim S. (2009) Stem cells in liver regeneration, fibrosis
and cancer: the good, the bad and the ugly. J Pathol 217:282–298.
20. Lorenzini S, Bird TG, Boulter L, Bellamy C, Samuel K, Aucott R et al.
(2010) Characterization of a stereotypical cellular and extracellular
adult liver progenitor cell niche in rodents and diseased human liver.
Gut 59:645–654.
21. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY et al. (2009)
EpCAM positive hepatocellular carcinoma cells are tumor initiating cells
with stem/progenitor cell features. Gastroenterology 136:1012–1024.
22. Marquardt JU, Factor VM, Thorgeirsson SS. (2010) Epigenetic regulation
of cancer stem cells in liver cancer: current concepts and clinical impli-
cations. J Hepatol 53:568–577.
23. Lingala S, Cui YY, Chen X, Ruebner BH, Qian XF, Zern MA et al. (2010)
Immunohistochemical staining of cancer stem cell markers in hepatocel-
lular carcinoma. Exp Mol Pathol 89:27–35.
24. Lee EK, Han GY, Park HW, Song YJ, Kim CW. (2010) Transgelin promotes
migration and invasion of cancer stem cells. J Proteome Res 9:5108–
5117.
25. Esteller M, Corn PG, Baylin SB, Herman JG. (2001) A gene hypermethy-
lation profile of human cancer. Cancer Res 61:3225–3229.
26. Waki T, Tamura G, Sato M, Motoyama T. (2003) Age-related methylation
of tumour suppressor and tumour-related genes: an analysis of autopsy
samples. Oncogene 22:4128–4133.
27. Farazi PA, DePinho RA. (2006) Hepatocellular carcinoma pathogenesis:
from genes to environment. Nat Rev Cancer 6:674–687.
28. Maeta Y, Shiota G, Okano J, Murawaki Y. (2005) Effect of promoter
methylation of the p16 gene on phosphorylation of retinoblastoma gene
product and growth of hepatocellular carcinoma cells. Tumour Biol
26:300–305.
29. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. (2003) Aberrant
CpG island hypermethylation along multistep hepatocarcinogenesis.
Am J Pathol 163:1371–1378.
30. Kaneto H, Sasaki S, Yamamoto H, Itoh F, Toyota M, Suzuki H et al. (2001)
Detection of hypermethylation of the p16(INK4A) gene promoter in
chronic hepatitis and cirrhosis associated with hepatitis B or C virus.
Gut 48:372–377.
31. Shim YH, Yoon GS, Choi HJ, Chung YH, Yu E. (2003) p16 Hypermethy-
lation in the early stage of hepatitis B virus-associated hepatocarcino-
genesis. Cancer Lett 190:213–219.
32. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. (2008)
Aberrant methylation of multiple tumour suppressor genes in ageing
liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 47:
908–918.
33. Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asakura H. (1999)
p16(INK4A) is inactivated by extensive CpG methylation in human hepa-
tocellular carcinoma. Gastroenterology 116:394–400.
34. Kanai Y, Ushijima S, Hui AM, Ochiai A, Tsuda H, Sakamoto M et al. (1997)
The E-cadherin gene is silenced by CpG methylation in human hepato-
cellular carcinomas. Int J Cancer 71:355–359.
35. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. (2000) Frequent p15
promoter methylation in tumour and peripheral blood from hepatocellular
carcinoma patients. Clin Cancer Res 6:3516–3521.
HPB 375
HPB 2011, 13, 369–376 © 2011 International Hepato-Pancreato-Biliary Association
36. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning
JE et al. (2001) SOCS-1, a negative regulator of the JAK/STAT pathway,
is silenced by methylation in human hepatocellular carcinoma and shows
growth-suppression activity. Nat Genet 28:29–35.
37. Du Y, Carling T, Fang W, Piao Z, Sheu JC, Huang S. (2001) Hypermethy-
lation in human cancers of the RIZ1 tumour suppressor gene, a member
of a histone/protein methyltransferase superfamily. Cancer Res 61:8094–
8099.
38. Archer KJ, Mas VR, Maluf DG, Fisher RA. (2010) High-throughput assess-
ment of CpG site methylation for distinguishing between HCV-cirrhosis
and HCV-associated hepatocellular carcinoma. Mol Genet Genomics
283:341–349.
39. Csepregi A, Rocken C, Hoffmann J, Gu P, Saliger S, Muller O et al. (2008)
APC promoter methylation and protein expression in hepatocellular car-
cinoma. J Cancer Res Clin Oncol 134:579–589.
40. He N, Park K, Zhang Y, Huang J, Lu S, Wang L. (2008) Epigenetic
inhibition of nuclear receptor small heterodimer partner is associated
with and regulates hepatocellular carcinoma growth. Gastroenterology
134:793–802.
41. Arasaradnam RP, Khoo KT, Bradburn M, Mathers JC, Kelly SB. (2010)
DNA methylation of ESR-1 and N-33 in colorectal mucosa of patients
with ulcerative colitis (UC). Epigenetics 5:422–426.
42. Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Mori Y et al. (2009) A multicentre,
double-blinded validation study of methylation biomarkers for progres-
sion prediction in Barrett's oesophagus. Cancer Res 69:4112–4115.
43. Clement G, Guilleret I, He B, Yagui-Beltran A, Lin YC, You L et al. (2008)
Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early
in the carcinogenesis of Barrett's oesophagus. Cancer Sci 99:46–53.
44. Liu H, Zhou Y, Boggs SE, Belinsky SA, Liu J. (2007) Cigarette smoke
induces demethylation of prometastatic oncogene synuclein-gamma in
lung cancer cells by downregulation of DNMT3B. Oncogene 26:5900–
5910.
45. Tang M, Xu W, Wang Q, Xiao W, Xu R. (2009) Potential of DNMT and its
epigenetic regulation for lung cancer therapy. Curr Genomics 10:336–
352.
46. Cheng Y, Zhang C, Zhao J, Wang C, Xu Y, Han Z et al. (2010) Correlation
of CpG island methylator phenotype with poor prognosis in hepatocel-
lular carcinoma. Exp Mol Pathol 88:112–117.
47. Sakamoto J, Fujiya M, Okamoto K, Nata T, Inaba Y, Moriichi K et al.
(2010) Immunoprecipitation of nucleosomal DNA is a novel procedure to
improve the sensitivity of serum screening for the p16 hypermethylation
associated with colon cancer. Cancer Epidemiol 34:194–199.
48. Glockner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J et al.
(2009) Methylation of TFPI2 in stool DNA: a potential novel biomarker for
the detection of colorectal cancer. Cancer Res 69:4691–4699.
49. Ehrlich M. (2002) DNA methylation in cancer: too much, but also too little.
Oncogene 21:5400–5413.
50. Lu B, Ma Y, Wu G, Tong X, Guo H, Liang A et al. (2008) Methylation
of Tip30 promoter is associated with poor prognosis in human hepato-
cellular carcinoma. Clin Cancer Res 14:7405–7412.
51. Jackson-Grusby L, Beard C, Possemato R, Tudor M, Fambrough D,
Csankovszki G et al. (2001) Loss of genomic methylation causes p53-
dependent apoptosis and epigenetic deregulation. Nat Genet 27:31–39.
52. Zhao J, Zhang X, Shi M, Xu H, Jin J, Ni H et al. (2006) TIP30 inhibits
growth of HCC cell lines and inhibits HCC xenografts in mice in combi-
nation with 5-FU. Hepatology 44:205–215.
53. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R et al. (2007)
Activation of p53 byMEG3 non-coding RNA. J Biol Chem 282:24731–
24742.
54. Zheng S, Chen P, McMillan A, Lafuente A, Lafuente MJ, Ballesta A et al.
(2000) Correlations of partial and extensive methylation at the p14(ARF)
locus with reduced mRNA expression in colorectal cancer cell lines and
clinicopathological features in primary tumours. Carcinogenesis 21:2057–
2064.
55. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC et al.
(1995) 5` CpG island methylation is associated with transcriptional silenc-
ing of the tumour suppressor p16/CDKN2/MTS1in human cancers.
Nat Med 1:686–692.
56. Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, Gouysse G,
McKay-Chopin S, Tavtigian SV et al. (2010) Hepatocellular carcinoma
displays distinct DNA methylation signatures with potential as clinical
predictors. PLoS ONE 5:e9749.
57. Artinyan A, Mailey B, Sanchez-Luege N, Khalili J, Sun CL, Bhatia S et al.
(2010) Race, ethnicity, and socioeconomic status influence the survival
of patients with hepatocellular carcinoma in the United States. Cancer
116:1367–1377.
58. Ng EK, Tsang WP, Ng SS, Jin HC, Yu J, Li JJ et al. (2009) MicroRNA-143
targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer
101:699–706.
59. Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H et al. (2003)
Increased protein expression of DNA methyltransferase (DNMT) 1 is
significantly correlated with the malignant potential and poor prognosis
of human hepatocellular carcinomas. Int J Cancer 105:527–532.
60. Bruix J, Sherman M. (2005) Management of hepatocellular carcinoma.
Hepatology 42:1208–1236.
61. Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz
LL et al. (2010) Advanced hepatocellular carcinoma: which staging
systems best predict prognosis? J Clin Oncol 28:2889–2895.
62. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A
et al. (2008) Gene expression in fixed tissues and outcome in hepatocel-
lular carcinoma. N Engl J Med 359:1995–2004.
63. Teodoridis JM, Hardie C, Brown R. (2008) CpG island methylator
phenotype (CIMP) in cancer: causes and implications. Cancer Lett 268:
177–186.
376 HPB
HPB 2011, 13, 369–376 © 2011 International Hepato-Pancreato-Biliary Association
